These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15358298)

  • 1. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
    Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity. Synthesis and biological evaluation of pyridine hydrazide derivatives.
    Galiano S; Erviti O; Pérez S; Moreno A; Juanenea L; Aldana I; Monge A
    Arzneimittelforschung; 2005; 55(2):81-5. PubMed ID: 15787274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel range based QSAR study of human neuropeptide Y (NPY) Y5 receptor inhibitors.
    Deswal S; Roy N
    Eur J Med Chem; 2007 Apr; 42(4):463-70. PubMed ID: 17083999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
    J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of neuropeptide Y receptors for the treatment of obesity.
    Sato N; Ogino Y; Mashiko S; Ando M
    Expert Opin Ther Pat; 2009 Oct; 19(10):1401-15. PubMed ID: 19743896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
    Levens NR; Della-Zuana O
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
    Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.
    Takahashi T; Sakuraba A; Hirohashi T; Shibata T; Hirose M; Haga Y; Nonoshita K; Kanno T; Ito J; Iwaasa H; Kanatani A; Fukami T; Sato N
    Bioorg Med Chem; 2006 Nov; 14(22):7501-11. PubMed ID: 16919461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
    J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
    Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
    Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
    Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
    Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
    Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.